-
1.发明申请Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof 有权抗体选择性肿瘤坏死因子相关凋亡诱导配体受体及其用途公开(公告)号：US20130243780A1
公开(公告)日：2013-09-19
申请号：US13621383
申请日：2012-09-17
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/30 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , G01N33/6863
摘要： An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 已经阐明了抗DR5抗体的核酸序列和氨基酸序列，并且已经产生含有和表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
2.发明授权Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists 有权与降低细胞凋亡诱导死亡受体激动剂抗性有关的药物和方法公开(公告)号：US08129124B2
公开(公告)日：2012-03-06
申请号：US11814551
申请日：2006-01-31
申请人： Tong Zhou , Robert P. Kimberly
发明人： Tong Zhou , Robert P. Kimberly
IPC分类号： G01N33/53 , G01N33/566 , C07K14/715 , C07K14/47 , C07K14/52
CPC分类号： G01N33/57492 , A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/40 , C07K2317/34 , C12Q1/6886 , G01N33/574 , G01N33/6863 , G01N2333/70578 , G01N2333/7151 , G01N2333/914 , G01N2500/02 , G01N2800/44 , Y02A50/412 , A61K2300/00
摘要： Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins.
摘要翻译： 本文提供了逆转或预防靶细胞对死亡受体激动剂的抗性的方法。 还提供筛选生物标志物抗性并监测对死亡受体激动剂的抗性的方法。 还提供了选择性诱导靶细胞凋亡的方法，用癌症治疗受试者，自身免疫性或炎性疾病，包括施用本文提供的组合物。 还提供了包含调节含CARD蛋白质的试剂的组合物。
-
3.发明申请Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof 有权抗体选择性肿瘤坏死因子相关凋亡诱导配体受体及其用途公开(公告)号：US20110008324A1
公开(公告)日：2011-01-13
申请号：US12822732
申请日：2010-06-24
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/30 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , G01N33/6863
摘要： An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和凋亡。 已经阐明了抗DR5抗体的核酸序列和氨基酸序列，并且已经产生含有和表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
4.发明授权Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof 有权抗肿瘤坏死因子相关凋亡诱导配体受体的选择性抗体及其用途公开(公告)号：US07790165B2
公开(公告)日：2010-09-07
申请号：US11760491
申请日：2007-06-08
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , C12N15/13
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/30 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , G01N33/6863
摘要： An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 已经阐明了抗DR5抗体的核酸序列和氨基酸序列，并且已经产生了含有并表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
公开(公告)号：US07713525B2
公开(公告)日：2010-05-11
申请号：US11877234
申请日：2007-10-23
申请人： Robert P. Kimberly , Tong Zhou , Takeshi Isoyama
发明人： Robert P. Kimberly , Tong Zhou , Takeshi Isoyama
IPC分类号： A61K39/395 , G01N33/53
CPC分类号： G01N33/5011 , G01N33/5088 , G01N33/57484 , G01N2333/4703 , G01N2333/908 , G01N2333/91225 , G01N2333/988
摘要： Disclosed herein are biomarkers and uses thereof for evaluating anti-cancer efficacy and sensitivity.
摘要翻译： 本文公开了用于评估抗癌功效和敏感性的生物标志物及其用途。
-
6.发明授权Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof 有权抗肿瘤坏死因子相关凋亡诱导配体受体的选择性抗体及其用途公开(公告)号：US08067001B2
公开(公告)日：2011-11-29
申请号：US12822732
申请日：2010-06-24
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/30 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , G01N33/6863
摘要： An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 已经阐明了抗DR5抗体的核酸序列和氨基酸序列，并且已经产生含有和表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
7.发明授权Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists 有权与降低细胞凋亡诱导死亡受体激动剂抗性有关的药物和方法公开(公告)号：US08476030B2
公开(公告)日：2013-07-02
申请号：US13356739
申请日：2012-01-24
申请人： Tong Zhou , Robert P. Kimberly
发明人： Tong Zhou , Robert P. Kimberly
IPC分类号： G01N33/53
CPC分类号： G01N33/57492 , A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/40 , C07K2317/34 , C12Q1/6886 , G01N33/574 , G01N33/6863 , G01N2333/70578 , G01N2333/7151 , G01N2333/914 , G01N2500/02 , G01N2800/44 , Y02A50/412 , A61K2300/00
摘要： Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins.
摘要翻译： 本文提供了逆转或预防靶细胞对死亡受体激动剂的抗性的方法。 还提供了筛选生物标志物抗性并监测对死亡受体激动剂的抗性的方法。 还提供了选择性诱导靶细胞凋亡的方法，用癌症治疗受试者，自身免疫性或炎性疾病，包括施用本文提供的组合物。 还提供了包含调节含CARD蛋白质的试剂的组合物。
-
8.发明授权Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof 有权抗肿瘤坏死因子相关凋亡诱导配体受体的选择性抗体及其用途公开(公告)号：US08329180B2
公开(公告)日：2012-12-11
申请号：US13269811
申请日：2011-10-10
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： A61K39/39558 , A61K2039/505 , C07K16/2878 , C07K16/30 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , G01N33/6863
摘要： An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 已经阐明了抗DR5抗体的核酸序列和氨基酸序列，并且已经产生含有和表达这些序列的载体和细胞。 具体涉及抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
公开(公告)号：US08119355B2
公开(公告)日：2012-02-21
申请号：US12723113
申请日：2010-03-12
申请人： Robert P. Kimberly , Tong Zhou , Takeshi Isoyama
发明人： Robert P. Kimberly , Tong Zhou , Takeshi Isoyama
IPC分类号： G01N33/53
CPC分类号： G01N33/5011 , G01N33/5088 , G01N33/57484 , G01N2333/4703 , G01N2333/908 , G01N2333/91225 , G01N2333/988
摘要： Disclosed herein are biomarkers and uses thereof for evaluating anti-cancer efficacy and sensitivity.
摘要翻译： 本文公开了用于评估抗癌功效和敏感性的生物标志物及其用途。
-
10.发明申请Combinations of Antibodies Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Other Therapeutic Agents 有权针对肿瘤坏死因子相关凋亡诱导配体受体和其他治疗剂的选择性抗体的组合公开(公告)号：US20090022707A1
公开(公告)日：2009-01-22
申请号：US11752153
申请日：2007-05-22
申请人： Robert P. Kimberly , William J. Koopman , Albert F. LoBuglio , Tong Zhou , Donald J. Buchsbaum , Kimihisa Ichikawa , Jun Oshumi
发明人： Robert P. Kimberly , William J. Koopman , Albert F. LoBuglio , Tong Zhou , Donald J. Buchsbaum , Kimihisa Ichikawa , Jun Oshumi
IPC分类号： A61K39/395 , A61P29/00 , A61P31/00
CPC分类号： C07K16/2878 , A61K31/337 , A61K31/519 , A61K39/39541 , A61K41/00 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.
摘要翻译： 本发明的抗体与人DR5或与人DR4相互作用以在受体下游产生激动或拮抗作用，包括抑制细胞增殖和细胞凋亡。 详细描述了任选与各种治疗剂组合的抗体的方法和用途，包括治疗凋亡相关疾病和治疗失调的细胞生长。
-
-
-
-
-
-
-
-
-
搜索结果
213 条记录 (耗时 0.046 秒)
